statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Final Trades: Freeport-McMoran, Pfizer, Danaher and United Rentals

Final Trades: Freeport-McMoran, Pfizer, Danaher and United Rentals...

European Commission Approves Pfizers DURVEQTIX (fidanacogene elaparvovec), a One-Time Gene Therapy for Adults with Hemophilia B

Pfizer Inc. (NYSE: PFE) today announced that the European Commission (EC) has granted conditional marketing authorization for DURVEQTIX (fidanacogene elaparvovec), a gene therapy for the treatment of...

AstraZeneca Posts Earnings Beat, Lifts Guidance on Strong Sales

SOPA Images / Contributor / Getty Images

 Key TakeawaysAstraZeneca's second-quarter earnings beat expectations Thursday, and the drugmaker also lifted its guidance.Like its COVID-19...

Beware, Wegovy -- Pfizer Is Working on a Competitor

Beware, Wegovy -- Pfizer Is Working on a Competitor...

The Media's Latest Pathetic Blame Game

The Media's Latest Pathetic Blame Game

 Authored by Ian Miller via The Brownstone Institute,

By late 2020, the media and public health establishment had two obsessions.

 One of their...

Sangamo Stock Spikes As Pfizer Partnership Meets Goal In Late-Stage Study

Pfizer's Phase 3 AFFINE study of giroctocogene fitelparvovec gene therapy for hemophilia A meets key endpoints, showing a significant reduction in annualized bleeding rate.
read more...

Pfizer's gene therapy for rare genetic bleeding disorder succeeds in late-stage trial

The hemophilia A treatment could become the company's second gene therapy to enter the U.S. market after Beqvez, which was cleared in April for hemophilia B...

Pfizer Announces Positive Topline Results From Phase 3 Study of Hemophilia A Gene Therapy Candidate

Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase 3 AFFINE study (NCT04370054) evaluating giroctocogene fitelparvovec, an investigational gene therapy for the treatment...

'Pure Blood': Dating Divide Over Vaccination Status Splits Those Looking For A Partner

'Pure Blood': Dating Divide Over Vaccination Status Splits Those Looking For A Partner

 Authored by Allan Stein via The Epoch Times (emphasis ours),

Courtney Furlong, 36, had always...

Oral Weight Loss Drugs Vs. Injections - Pills Are Promising Yet Challenging Frontier

Pharmaceutical giants like Roche, Eli Lilly, Novo Nordisk, and Pfizer are racing to develop oral weight loss medications. These drugs promise to complement existing injectables, offering new hope in...

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Volume	35.66M
52-Wk High	$37.19
52-Wk Low	$25.20

PFE Pfizer Inc

About

Feed

News

Sentiment

Earnings

Fundamentals